Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.78 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.78 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203454 | 0.97 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| Rolofylline SCHEMBL720438 | 0.88 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| SCHEMBL14051422 | 0.86 | ADORA1 (0.91) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| SCHEMBL8392964 | 0.83 | ADORA2B (0.78) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| SCHEMBL8394321 | 0.83 | ADORA2B (0.78) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| Rolofylline SCHEMBL13414105 | 0.83 | ADORA1 (0.86) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| Rolofylline SCHEMBL13414155 | 0.82 | ADORA1 (0.88) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| SCHEMBL7270718 | 0.82 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| SCHEMBL8705557 | 0.82 | ADORA1 (0.92) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 | |
| SCHEMBL8705276 | 0.82 | ADORA1 (0.82) | ADORA1ADORA3ADORA2AADORA2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | MUGERDITICHIAN MARK | 2008-03-20 | — | — | US | disclosed |
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | MUGERDITICHIAN MARK | 2008-03-20 | — | — | US | disclosed |
| WO-2008024277-A2 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | NOVACARDIA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | DCX, FLT4, KDR | ADORA1 637/4885ADORA3 227/4885ADORA2A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.